How did Annovis Bio's operating expenses trend in Q4 2024?

Annovis Bio's operating expenses for Q4 2024 are not currently available. However, the company's financial results for the third quarter ending September 30, 2024, provide insight into its spending patterns. During this period, the company's total operating expenses were $4 million. Given that Annovis Bio had a cash and cash equivalents balance of $13.6 million as of November 8, 2024, and had received $4.4 million in net cash from the exercises of Canaccord Warrants during the third quarter, it is reasonable to assume that the company had sufficient liquidity to cover its operating expenses in Q4 2024. The company's focus on securing additional funds through strategic initiatives, such as the $50 million At-The-Market offering, also indicates a proactive approach to managing financial resources.